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Healthcare reform in South Africa (SA) has been an 
ongoing process since 1994. By 2011, this process had 
evolved into a broad-based National Health Insurance 
(NHI) policy with compulsory membership for all 
citizens, based on a basic benefit package.
Yet another milestone was reached with the publication of the 
Medicines and Related Substances Act (Act 101/1965) guidelines for 
pharmacoeconomic (PE) submissions.[1] The guidelines attempt to 
regulate and enhance a transparent pricing system for medicines and 
scheduled substances and offer structure for PE submissions. These 
guidelines came into effect on 1 April 2013.
Background
Three components ‘anchor’ the guidelines:
• they provide for voluntary submissions
• they apply to medicines that are registered by the Medicines 
Control Council in SA
• they apply to the private healthcare sector.
In the first part of the guidelines (Process for Submission), three of 
the stated objectives of the guidelines need to be highlighted. Firstly, 
there is a clear objective to move towards standardisation of PE 
evaluations. Secondly, there is an attempt to promote transparency 
when it comes to the value of medicine. The latter is important, as it is 
an attempt at medicine value transparency and not price transparency. 
The third objective is ‘to create a forum which provides an objective 
review of the value of medicine’, the key word being objective.
The Pricing Committee (PC) will be responsible for establishing the 
‘terms of reference for a sub-committee to assess pharmacoeconomic 
submissions’. This is an important guideline, with far-reaching 
implications, as all medicines that are found to be unreasonably 
priced will be listed on the National Department of Health website. 
This regulation specifically mentions ‘unreasonably priced’ and does 
not address ‘value of medicine’.
Furthermore, the PC may only make three recommendations 
on the therapeutic value of submitted medicines. Firstly, it may 
recommend that a medicine does not offer therapeutic value relative 
to the single exit price (SEP). Secondly, it may recommend that 
it is unreasonably priced. Lastly, it may make recommendations 
with regard to its therapeutic value in a specific patient group or 
prescription by general practitioners or specialist groups, or under 
specific circumstances. This implies that there is no mechanism 
or mandate whereby the PC can make a recommendation that a 
medicine does in fact offer therapeutic value relative to the SEP or 
that it is reasonably priced.
The second part of the guidelines pertains to the content of PE 
evaluation submissions and addresses some technical issues that 
need to be complied with. It addresses critical issues such as the 
availability of SA clinical data v. international data, acceptable 
evidence (e.g. randomised controlled trials), co-administered drugs, 
choice of comparator drugs, and, very importantly, clinical evidence 
of effectiveness. The latter two require special mention as they have 
far-reaching implications.
With regard to the choice of a comparator medicine, the guidelines 
make it clear that the main comparator should be the current 
standard of care for local practice and go on to state ‘... such as those 
described in the Prescribed Minimum Benefits (PMB) and Essential 
Drugs List (EDL)’.
The guidelines related to clinical outcomes (effectiveness) are 
comprehensive and directive and constitute the most important 
part of a PE submission. However, some important aspects that 
should be highlighted are a recommendation to include details of 
patient adherence to treatment data, SA quality of life measures, and 
transparency and completeness of search strategies for relevant data.
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One technical aspect that needs to be highlighted is the requirement 
to perform the PE evaluation from a third-party payer perspective. 
This implies that only the economic costs that are relevant to a third-
party payer should be included in the submission. Accordingly, only 
direct healthcare costs should be included, with exclusion of other 
societal costs such as direct non-healthcare costs (transport and 
caretaker costs and loss of income directly associated with the disease 
treatment and progression) and non-direct healthcare costs (loss of 
productivity and the macro-economic impact on the SA economy).
The guidelines constitute ‘world class’ standards for PE evaluation 
submission and should be seen as complementary to a world-class 
private healthcare sector. Furthermore, they are comprehensive and 
directive and a significant step towards the standardisation of PE 
evaluation submissions. There is a very strong emphasis on clinical 
outcomes and the robustness of the supporting evidence, and to what 
extent the latter is transferable and applicable in SA. Mathematical 
modelling, when needed to mimic the natural history of the disease 
and estimate its economic impact by comparing a new medicine to 
the current practices, appears to be less important.
Implications
Several important implications need to be considered. Firstly, the PE 
guidelines are published as a Regulation to the Medicines and Related 
Substances Act (Act 101/1965). They therefore have no direct bearing 
on medical schemes (third-party payers in the private healthcare 
sector), which are regulated by the Medical Schemes Act (Act 131 
of 1998, as amended). Although a manufacturer might submit a PE 
evaluation to the PC and receive a ‘non-negative’ outcome, this does 
not imply reimbursement by third-party payers. Medical schemes 
may or may not accept the outcome of ‘good value for money’ and 
will retain the right not to reimburse such new medicines based on 
arguments of affordability.
Although the Regulations clearly state that PE submissions are 
voluntary, this could be questioned. Paragraph 3, which deals 
with the criteria for medicines that require PE submissions, states 
three criteria and under 3(c) states: ‘Where it is the opinion of 
the Minister, Pricing Committee or the Director-General (DG) 
that a pharmacoeconomic submission is necessary/required for a 
particular medicine.’ This implies that a PE submission may become 
compulsory if it is so decided.
The guidelines are merely a first step towards a bigger plan in terms 
of transparency of the value of medicine in an NHI dispensation. 
This begs the question whether objectivity in a private healthcare 
system constitutes objectivity in a more societal system, such as NHI. 
Can committee members be or remain objective in an ever-changing 
health reform agenda, i.e. from a private healthcare focus towards an 
NHI-focused perspective?
The broad statement about the terms of reference that will be 
provided by the PC to the sub-committee ties in with the question 
of objectivity. In pharmacoeconomics, cost-effectiveness is based 
on a society’s willingness-to-pay thresholds for specific benefits. It 
is considered an indication from society of what constitutes good 
value for money. On what basis will the PE sub-committee make 
recommendations in an objective way regarding a submission? What 
would their threshold for cost-effectiveness be?
Given the three recommendations that could be made by the PC, 
based on a PE submission, what incentives would there be for a 
pharmaceutical company to voluntarily submit a PE evaluation?
Conclusion
The comprehensive nature of the guidelines implies that it will be a 
costly project to submit a PE evaluation in line with the Regulations. 
These additional costs should, however, be considered against the 
backdrop of a shrinking private healthcare industry that is envisaged 
as NHI is rolled out. In this scenario, pharmaceutical companies 
could find it more challenging to remain profitable in SA. This will be 
dependent on the company’s specific product portfolio and pipeline. 
Given this challenge, it is quite probable that some pharmaceutical 
companies will exit the SA market.
The publication of the PE guidelines should be considered a 
first step towards the creation of a mechanism whereby the value 
of medicine can be quantified in a transparent manner. It can be 
expected that voluntary submissions of PE studies will progressively 
move towards compulsory PE submissions. Stakeholders should 
therefore plan to build and enhance capacity, knowledge and insight 
related to pharmacoeconomics. Finally, in the future we may witness 
the progressive conversion of the guidelines in support of the NHI 
initiative and EDL extensions.
Strategically, stakeholders should not only ensure that they 
understand the content and implications of the PE guidelines, 
but also plan how they will position themselves in this changing 
environment.
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